Suspected ciprofloxacin inhibition of olanzapine resulting in increased plasma concentration.
Markowitz
J S
JS
DeVane
C L
CL
D000890:Anti-Infective Agents / Q000494:pharmacology; D014150:Antipsychotic Agents / Q000037:antagonists & inhibitors / Q000097:blood*; D001569:Benzodiazepines; D002939:Ciprofloxacin / Q000494:pharmacology*; D019388:Cytochrome P-450 CYP1A2 / Q000096:biosynthesis / Q000378:metabolism; D065609:Cytochrome P-450 CYP1A2 Inhibitors; D003865:Major Depressive Disorder / Q000378:metabolism; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D004794:Enzyme Repression / Q000187:drug effects; D005260:Female; D006801:Humans; D008875:Middle Aged; D000077152:Olanzapine; D010890:Pirenzepine / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors / Q000097:blood
D000890:Anti-Infective Agents; D014150:Antipsychotic Agents; D065609:Cytochrome P-450 CYP1A2 Inhibitors; D004791:Enzyme Inhibitors; D001569:Benzodiazepines; D010890:Pirenzepine; D002939:Ciprofloxacin; D019388:Cytochrome P-450 CYP1A2; D000077152:Olanzapine